Monitor upcoming FDA IND meeting for TBS-2025 and Phase 3 enrollment updates for IFx-2.0. The $50M credit facility reduces near-term dilution risk but carries a 12% interest cost. Key catalysts are binary clinical trial readouts expected in 2H 2027.
Price Chart
Executive Summary
TuHURA Biosciences reported Q1 2026 financial results with no revenue and a net loss per share of -$0.17, missing the consensus estimate of -$0.11. The company highlighted a $50 million credit facility established in April 2026 to extend cash runway into 2028, and FDA Orphan Drug Designation for IFx-2.0 in melanoma. The filing is neutral as it is a pre-revenue clinical-stage biotech with no material change in fundamentals; the credit facility provides non-dilutive capital but carries a 12% interest rate.
Key Financial Metrics
Key Facts
- Cash and cash equivalents of $6.3 million at March 31, 2026
- Common shares outstanding approximately 63.6 million
- Research and development expenses $5.2 million for Q1 2026 vs $4.6 million in Q1 2025
- General and administrative expenses $2.3 million for Q1 2026 vs $2.0 million in Q1 2025
- Net cash outflows from operating activities ($4.4) million for Q1 2026 vs ($4.7) million in Q1 2025
- Net cash flows from financing activities $7.2 million for Q1 2026 vs ($0.5) million in Q1 2025
- Established a $50 million credit facility in April 2026 with 12% annual interest, maturing April 21, 2031
- Received FDA Orphan Drug Designation for IFx-2.0 in stage IIB to stage IV cutaneous melanoma
- Phase 3 trial of IFx-2.0 in Merkel Cell Carcinoma enrollment completion expected in 2H 2027
- EPS of -$0.17 missed consensus estimate of -$0.11
Financial Impact
No revenue; cash burn of $4.4M in operating activities; $50M credit facility provides runway into 2028
Risk Factors
- Pre-revenue clinical-stage company with no approved products
- Cash and equivalents of $6.3M may require additional financing before Phase 3 data readout in 2H 2027
- Credit facility carries 12% annual interest, increasing financial leverage
- Clinical trial risks: patient enrollment, data outcomes, regulatory interactions
- EPS miss of 54.5% vs consensus may pressure stock
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-227204 |
| Document: hura-ex99_1.htm | 0001193125-26-227204 |
| Document: 0001193125-26-227204-index-headers.html | 0001193125-26-227204 |
| Document: 0001193125-26-227204-index.html | 0001193125-26-227204 |
| Document: 0001193125-26-227204.txt | 0001193125-26-227204 |
| 8-K Data (Synthetic) | 0001193125-26-227204 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 8-K | $1.78 | awaiting T+60 | — | $2.05 (+14.89%) |
Sep 24, 2026 4w ago | 8-K | $2.10 | awaiting T+60 | — | $2.05 (−2.62%) |
Sep 17, 2026 5w ago | 8-K | $2.10 | awaiting T+60 | — | $2.05 (−2.62%) |
Sep 16, 2026 5w ago | 8-K | $2.09 | awaiting T+60 | — | $2.05 (−2.15%) |
Sep 4, 2026 7w ago | 8-K | $2.12 | awaiting T+60 | — | $2.05 (−3.54%) |
Aug 19, 2026 9w ago | 8-K | $2.22 | awaiting T+60 | — | $2.05 (−7.88%) |
Aug 14, 2026 10w ago | 8-K | $2.47 | awaiting T+60 | — | $2.05 (−17.21%) |
Aug 14, 2026 10w ago | Press Release | $2.47 | awaiting T+60 | — | $2.05 (−17.21%) |
Aug 13, 2026 10w ago | 8-K | $2.47 | awaiting T+60 | — | $2.05 (−17.21%) |
Jul 29, 2026 12w ago | 8-K | $2.17 $2.18 | ▲ +0.46% | ▼ −2.00% | $2.05 (−5.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers